APA (7th ed.) Citation

G, L., F, C., NG, M., PK, A., R, A., R, A., . . . AJ, P. (2022). Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: A preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Lancet (London, England), 399(10342), 2212. https://doi.org/10.1016/S0140-6736(22)00770-X

Chicago Style (17th ed.) Citation

G, Li, et al. "Safety and Immunogenicity of the ChAdOx1 NCoV-19 (AZD1222) Vaccine in Children Aged 6-17 Years: A Preliminary Report of COV006, a Phase 2 Single-blind, Randomised, Controlled Trial." Lancet (London, England) 399, no. 10342 (2022): 2212. https://doi.org/10.1016/S0140-6736(22)00770-X.

MLA (9th ed.) Citation

G, Li, et al. "Safety and Immunogenicity of the ChAdOx1 NCoV-19 (AZD1222) Vaccine in Children Aged 6-17 Years: A Preliminary Report of COV006, a Phase 2 Single-blind, Randomised, Controlled Trial." Lancet (London, England), vol. 399, no. 10342, 2022, p. 2212, https://doi.org/10.1016/S0140-6736(22)00770-X.